I will start in a general way, Mr. Fletcher. As you probably know, the committee is well aware that these products were submitted to the FDA at a similar time as they were to us. The FDA conducted a very extensive review as well, very similar to what we did, and basically came up with the same kinds of conclusions that we did, again, quite independently. Also, one of the key conditions of licensing for the FDA is the post-approval study, the long-term study. So I think it is a very important common conclusion for the two agencies. The requirement for the manufacturer to maintain the patient registry is also common.
Basically, the two decisions were very, very similar.